{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:59:06Z","timestamp":1790366346602,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cost Eff Resour Alloc"],"DOI":"10.1186\/s12962-026-00781-6","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T10:16:59Z","timestamp":1787825819000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness analysis of linezolid versus vancomycin in the treatment of adult hospital-acquired and ventilator-associated methicillin-resistant staphylococcus Aureus Pneumonia (a systematic review)"],"prefix":"10.1186","volume":"24","author":[{"given":"Efat Mohebi","family":"Moghadam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Jahangiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Hadian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"781_CR1","unstructured":"NICE. Pneumonia: diagnosis and management. NICE. 2025."},{"key":"781_CR2","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1164\/rccm.200405-644ST","volume":"171","author":"American Thoracic Society","year":"2005","unstructured":"American Thoracic Society. Infectious Diseases Society of America: Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388\u2013416.","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"781_CR3","doi-asserted-by":"publisher","first-page":"883","DOI":"10.26719\/2013.19.10.883","volume":"19","author":"S Afhami","year":"2013","unstructured":"Afhami S, Hadadi A, Khorami E, Seifi A, Bazaz NE. Ventilator-associated pneumonia in a teaching hospital in Tehran and use of the Iranian Nosocomial Infections Surveillance Software. East Mediterr Health J. 2013;19(10):883\u20137.","journal-title":"East Mediterr Health J"},{"key":"781_CR4","first-page":"191","volume":"9","author":"AR Machado","year":"2005","unstructured":"Machado AR, Arns CC, Follador W, Guerra A. Cost-effectiveness of linezolid versus vancomycin in mechanical ventilation-associated nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus. Brazilian J Infect Dis. 2005;9:191\u2013200.","journal-title":"Brazilian J Infect Dis"},{"issue":"3","key":"781_CR5","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1097\/MCP.0000000000000042","volume":"20","author":"VI Enne","year":"2014","unstructured":"Enne VI, Personne Y, Grgic L, Gant V, Zumla A. Aetiology of hospital-acquired pneumonia and trends in antimicrobial resistance. Curr Opin Pulm Med. 2014;20(3):252\u20138.","journal-title":"Curr Opin Pulm Med"},{"issue":"11","key":"781_CR6","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1086\/591861","volume":"29","author":"AI Hidron","year":"2008","unstructured":"Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006\u20132007. Infect Control Hosp Epidemiol. 2008;29(11):996\u20131011.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"12","key":"781_CR7","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.3201\/eid1312.070629","volume":"13","author":"E Klein","year":"2007","unstructured":"Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999\u20132005. Emerg Infect Dis. 2007;13(12):1840.","journal-title":"Emerg Infect Dis"},{"issue":"8","key":"781_CR8","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1001\/jama.1995.03530080055041","volume":"274","author":"J-L Vincent","year":"1995","unstructured":"Vincent J-L, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin M-H, et al. The prevalence of nosocomial infection in intensive care units in Europe: results of the European Prevalence of Infection in Intensive Care (EPIC) Study. JAMA. 1995;274(8):639\u201344.","journal-title":"JAMA"},{"issue":"1","key":"781_CR9","doi-asserted-by":"publisher","first-page":"164","DOI":"10.4103\/jdmimsu.jdmimsu_762_24","volume":"20","author":"VH Mishra","year":"2025","unstructured":"Mishra VH, Ugemuge S, Bhrushandi M. Hospital-acquired Infections: The Challenge of Methicillin-resistant Staphylococcus aureus. J Datta Meghe Inst Med Sci Univ. 2025;20(1):164\u20135.","journal-title":"J Datta Meghe Inst Med Sci Univ"},{"issue":"9","key":"781_CR10","doi-asserted-by":"publisher","first-page":"751","DOI":"10.2165\/00019053-200725090-00004","volume":"25","author":"AF Shorr","year":"2007","unstructured":"Shorr AF. Epidemiology and economic impact of meticillin-resistant Staphylococcus aureus: review and analysis of the literature. PharmacoEconomics. 2007;25(9):751\u201368.","journal-title":"PharmacoEconomics"},{"issue":"3","key":"781_CR11","doi-asserted-by":"publisher","first-page":"e104447","DOI":"10.5812\/iji.104447","volume":"7","author":"MJ Hasan","year":"2020","unstructured":"Hasan MJ, Nessa SST, Rabbani R. Comparative evaluation of linezolid and teicoplanin in the treatment of ventilator-associated mrsa pneumonia: a single-center experience. Int J Infect. 2020;7(3):e104447.","journal-title":"Int J Infect"},{"key":"781_CR12","unstructured":"Mohamad MRA, Mahnaz A, Parvaneh E. Prevalence of nosocomial infections in Iranian hospitals: a systematic review and meta-analysis. 2020."},{"key":"781_CR13","unstructured":"Center for Infectious Disease Management. Report on Iran\u2019s Hospital Infection Control Program in 2019 Ministry of Health and Medical Education Deputy Minister of Health; 1400."},{"issue":"2","key":"781_CR14","doi-asserted-by":"publisher","first-page":"78","DOI":"10.4103\/0974-777X.157245","volume":"7","author":"DC Kaur","year":"2015","unstructured":"Kaur DC, Chate SS. Study of antibiotic resistance pattern in methicillin resistant Staphylococcus aureus with special reference to newer antibiotic. J global Infect Dis. 2015;7(2):78\u201384.","journal-title":"J global Infect Dis"},{"issue":"5","key":"781_CR15","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1093\/cid\/ciw353","volume":"63","author":"AC Kalil","year":"2016","unstructured":"Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61\u2013111.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"781_CR16","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ijantimicag.2011.09.028","volume":"39","author":"IM Gould","year":"2012","unstructured":"Gould IM, David MZ, Esposito S, Garau J, Lina G, Mazzei T, et al. New insights into meticillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance. Int J Antimicrob Agents. 2012;39(2):96\u2013104.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"781_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jac\/dkae380","volume":"80","author":"A Ishak","year":"2025","unstructured":"Ishak A, Mazonakis N, Spernovasilis N, Akinosoglou K, Tsioutis C. Bactericidal versus bacteriostatic antibacterials: clinical significance, differences and synergistic potential in clinical practice. J Antimicrob Chemother. 2025;80(1):1\u201317.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"781_CR18","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1177\/0897190008318501","volume":"21","author":"KA Wargo","year":"2008","unstructured":"Wargo KA, Eiland EH III, Eiland LS. Management and Treatment Considerations for Infections Caused by Methicillin-Resistant Staphylococcus aureus. J Pharm Pract. 2008;21(5):324\u201336.","journal-title":"J Pharm Pract"},{"key":"781_CR19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/1469-0691.12450","volume":"20","author":"J Chastre","year":"2014","unstructured":"Chastre J, Blasi F, Masterton R, Rello J, Torres A, Welte T. European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant S taphylococcus aureus after more than 10 years of experience with linezolid. Clin Microbiol Infect. 2014;20:19\u201336.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"781_CR20","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jmii.2015.08.002","volume":"49","author":"P-C Lin","year":"2016","unstructured":"Lin P-C, Wang BC, Kim R, Magyar A, Lai C-C, Yang Y-W, et al. Estimating the cost-effectiveness of linezolid for the treatment of methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Taiwan. J Microbiol Immunol Infect. 2016;49(1):46\u201351.","journal-title":"J Microbiol Immunol Infect"},{"issue":"8","key":"781_CR21","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/j.clinthera.2006.08.016","volume":"28","author":"CD Mullins","year":"2006","unstructured":"Mullins CD, Kuznik A, Shaya FT, Obeidat NA, Levine AR, Liu LZ, et al. Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Ther. 2006;28(8):1184\u201398.","journal-title":"Clin Ther"},{"issue":"9","key":"781_CR22","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.clinthera.2014.06.029","volume":"36","author":"MS Niederman","year":"2014","unstructured":"Niederman MS, Chastre J, Solem CT, Wan Y, Gao X, Myers DE, et al. Health economic evaluation of patients treated for nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus: secondary analysis of a multicenter randomized clinical trial of vancomycin and linezolid. Clin Ther. 2014;36(9):1233\u201343. e1.","journal-title":"Clin Ther"},{"issue":"suppl2","key":"781_CR23","first-page":"ii27","volume":"51","author":"MH Wilcox","year":"2003","unstructured":"Wilcox MH. Efficacy of linezolid versus comparator therapies in Gram-positive infections. J Antimicrob Chemother. 2003;51(suppl2):ii27\u201335.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"781_CR24","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1093\/jac\/dkh048","volume":"53","author":"JA Cepeda","year":"2004","unstructured":"Cepeda JA, Whitehouse T, Cooper B, Hails J, Jones K, Kwaku F, et al. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study. J Antimicrob Chemother. 2004;53(2):345\u201355.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"781_CR25","doi-asserted-by":"publisher","first-page":"R118","DOI":"10.1186\/cc13914","volume":"18","author":"P Peyrani","year":"2014","unstructured":"Peyrani P, Wiemken TL, Kelley R, Zervos MJ, Kett DH, File TM Jr, et al. Higher clinical success in patients with ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus treated with linezolid compared with vancomycin: results from the IMPACT-HAP study. Crit Care. 2014;18(3):R118.","journal-title":"Crit Care"},{"issue":"4","key":"781_CR26","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.cmi.2017.08.028","volume":"24","author":"R Agarwal","year":"2018","unstructured":"Agarwal R, Bartsch SM, Kelly BJ, Prewitt M, Liu Y, Chen Y, et al. Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: systematic review, network meta-analysis and cost analysis. Clin Microbiol Infect. 2018;24(4):361\u20138.","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"781_CR27","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.ijantimicag.2012.12.012","volume":"41","author":"MM An","year":"2013","unstructured":"An MM, Shen H, Zhang JD, Xu GT, Jiang YY. Linezolid versus vancomycin for meticillin-resistant Staphylococcus aureus infection: a meta-analysis of randomised controlled trials. Int J Antimicrob Agents. 2013;41(5):426\u201333.","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"781_CR28","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.ijantimicag.2012.08.004","volume":"40","author":"M Bally","year":"2012","unstructured":"Bally M, Dendukuri N, Sinclair A, Ahern SP, Poisson M, Brophy J. A network meta-analysis of antibiotics for treatment of hospitalised patients with suspected or proven meticillin-resistant Staphylococcus aureus infection. Int J Antimicrob Agents. 2012;40(6):479\u201395.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"781_CR29","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S1473-3099(07)70312-2","volume":"8","author":"ME Falagas","year":"2008","unstructured":"Falagas ME, Siempos II, Vardakas KZ. Linezolid versus glycopeptide or \u03b2-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis. 2008;8(1):53\u201366.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"781_CR30","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13756-019-0518-2","volume":"8","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Wang Y, Van Driel ML, McGuire TM, Zhang T, Dong Y, et al. Network meta-analysis and pharmacoeconomic evaluation of antibiotics for the treatment of patients infected with complicated skin and soft structure infection and hospital-acquired or ventilator-associated penumonia. Antimicrob Resist Infect Control. 2019;8(1):72.","journal-title":"Antimicrob Resist Infect Control"},{"issue":"7","key":"781_CR31","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1517\/14656566.7.7.885","volume":"7","author":"L Wang","year":"2006","unstructured":"Wang L, Barrett JF. Pharmacoeconomics of treatment with the newer anti-Gram-positive agents. Expert Opin Pharmacother. 2006;7(7):885\u201397.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"781_CR32","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/cbdd.12417","volume":"85","author":"TI Verhoef","year":"2015","unstructured":"Verhoef TI, Morris S. Cost-effectiveness and pricing of antibacterial drugs. Chem Biol Drug Des. 2015;85(1):4\u201313.","journal-title":"Chem Biol Drug Des"},{"issue":"1","key":"781_CR33","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jval.2021.10.008","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated health economic evaluation reporting standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II good practices task force. Value health. 2022;25(1):10\u201331.","journal-title":"Value health"},{"issue":"5","key":"781_CR34","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.jval.2015.04.007","volume":"18","author":"CD Collins","year":"2015","unstructured":"Collins CD, Schwemm AK. Linezolid versus vancomycin in the empiric treatment of nosocomial pneumonia: a cost-utility analysis incorporating results from the ZEPHyR trial. Value health. 2015;18(5):614\u201321.","journal-title":"Value health"},{"issue":"4","key":"781_CR35","doi-asserted-by":"publisher","first-page":"R157","DOI":"10.1186\/cc13996","volume":"18","author":"DA Patel","year":"2014","unstructured":"Patel DA, Shorr AF, Chastre J, Niederman M, Simor A, Stephens JM, et al. Modeling the economic impact of linezolid versus vancomycin in confirmed nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus. Crit Care. 2014;18(4):R157.","journal-title":"Crit Care"},{"issue":"2","key":"781_CR36","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s15010-008-8046-7","volume":"37","author":"E De Cock","year":"2009","unstructured":"De Cock E, Krueger W, Sorensen S, Baker T, Hardewig J, Duttagupta S, et al. Cost-effectiveness of linezolid vs vancomycin in suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Germany. Infection. 2009;37(2):123\u201332.","journal-title":"Infection"},{"key":"781_CR37","doi-asserted-by":"crossref","unstructured":"Patel DA, Michel A, Stephens J, Weber B, Petrik C, Charbonneau C. An economic model to compare linezolid and vancomycin for the treatment of confirmed methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Germany. Infection and drug resistance. 2014:273\u2009\u2013\u200980.","DOI":"10.2147\/IDR.S68658"},{"issue":"2","key":"781_CR38","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1179\/joc.2005.17.2.203","volume":"17","author":"S Grau","year":"2005","unstructured":"Grau S, Alvarez-Lerma F, Del Castillo A, Neipp R, Rubio-Terres C. Cost-effectiveness analysis of the treatment of ventilator-associated pneumonia with linezolid or vancomycin in Spain. J Chemother. 2005;17(2):203\u201311.","journal-title":"J Chemother"},{"key":"781_CR39","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.vhri.2014.03.002","volume":"3","author":"SC Tan","year":"2014","unstructured":"Tan SC, Wang X, Wu B, Kang H, Li Q, Chen Y, et al. Cost-effectiveness of linezolid versus vancomycin among patients with methicillin-resistant Staphylococcus aureus confirmed nosocomial pneumonia in China. Value Health Reg Issues. 2014;3:94\u2013100.","journal-title":"Value Health Reg Issues"},{"issue":"1","key":"781_CR40","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12879-023-08961-y","volume":"24","author":"JA Buend\u00eda","year":"2024","unstructured":"Buend\u00eda JA, Pati\u00f1o DG, Zuluaga Salazar AF. Cost-effectiveness of linezolid to ventilator-associated pneumonia in Colombia. BMC Infect Dis. 2024;24(1):98.","journal-title":"BMC Infect Dis"},{"issue":"3","key":"781_CR41","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1007\/s00134-003-2088-1","volume":"30","author":"MH Kollef","year":"2004","unstructured":"Kollef MH, Rello J, Cammarata SK, Croos-Dabrera RV, Wunderink RG. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med. 2004;30(3):388\u201394.","journal-title":"Intensive Care Med"},{"issue":"5","key":"781_CR42","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/S0012-3692(15)33412-7","volume":"124","author":"RG Wunderink","year":"2003","unstructured":"Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest. 2003;124(5):1789\u201397.","journal-title":"Chest"},{"key":"781_CR43","doi-asserted-by":"crossref","unstructured":"Edlin R, McCabe C, Hulme C, Hall P, Wright J. Cost effectiveness modelling for health technology assessment: a practical course. Springer; 2015.","DOI":"10.1007\/978-3-319-15744-3"},{"issue":"9","key":"781_CR44","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1097\/CCM.0b013e3181eb3b96","volume":"38","author":"AC Kalil","year":"2010","unstructured":"Kalil AC, Murthy MH, Hermsen ED, Neto FK, Sun J, Rupp ME. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis. Crit Care Med. 2010;38(9):1802\u20138.","journal-title":"Crit Care Med"},{"issue":"5","key":"781_CR45","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1378\/chest.10-1556","volume":"139","author":"AJ Walkey","year":"2011","unstructured":"Walkey AJ, O\u2019Donnell MR, Wiener RS. Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials. Chest. 2011;139(5):1148\u201355.","journal-title":"Chest"},{"issue":"2","key":"781_CR46","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1097\/QCO.0000000000000640","volume":"33","author":"C Domined\u00f2","year":"2020","unstructured":"Domined\u00f2 C, Ceccato A, Torres A. Ventilator-associated pneumonia: new principles guiding empiric antibiotic therapy. Curr Opin Infect Dis. 2020;33(2):182\u20138.","journal-title":"Curr Opin Infect Dis"},{"issue":"1","key":"781_CR47","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/s13104-015-1202-0","volume":"8","author":"B Tsoi","year":"2015","unstructured":"Tsoi B, O\u2019Reilly D, Jegathisawaran J, Tarride J, Blackhouse G, Goeree R. Systematic narrative review of decision frameworks to select the appropriate modelling approaches for health economic evaluations. BMC Res Notes. 2015;8(1):244.","journal-title":"BMC Res Notes"},{"key":"781_CR48","doi-asserted-by":"crossref","unstructured":"Arnold RJ. Pharmacoeconomics: from theory to practice. CRC. 2016.","DOI":"10.1201\/9781420084405"},{"key":"781_CR49","unstructured":"Elliott R, Payne K. Essentials of economic evaluation in healthcare. Pharmaceutical. 2005."},{"issue":"4","key":"781_CR50","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.jhin.2020.09.012","volume":"106","author":"AP Wagner","year":"2020","unstructured":"Wagner AP, Enne VI, Livermore DM, Craig JV, Turner DA, Group IS. Review of health economic models exploring and evaluating treatment and management of hospital-acquired pneumonia and ventilator-associated pneumonia. J Hosp Infect. 2020;106(4):745\u201356.","journal-title":"J Hosp Infect"},{"issue":"1","key":"781_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00003246-200301000-00001","volume":"31","author":"DC Angus","year":"2003","unstructured":"Angus DC, Linde-Zwirble WT, Clermont G, Ball DE, Basson BR, Ely EW, et al. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med. 2003;31(1):1\u201311.","journal-title":"Crit Care Med"},{"issue":"13","key":"781_CR52","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1001\/jama.1997.03540370048035","volume":"277","author":"AA Quartin","year":"1997","unstructured":"Quartin AA, Schein RM, Kett DH, Peduzzi PN. Magnitude and duration of the effect of sepsis on survival. JAMA. 1997;277(13):1058\u201363.","journal-title":"JAMA"},{"issue":"8","key":"781_CR53","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S0002-9343(00)00591-X","volume":"109","author":"MB Hamel","year":"2000","unstructured":"Hamel MB, Phillips RS, Davis RB, Teno J, Connors AF Jr, Desbiens N, et al. Outcomes and cost-effectiveness of ventilator support and aggressive care for patients with acute respiratory failure due to pneumonia or acute respiratory distress syndrome. Am J Med. 2000;109(8):614\u201320.","journal-title":"Am J Med"}],"container-title":["Cost Effectiveness and Resource Allocation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12962-026-00781-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-026-00781-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-026-00781-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:02:36Z","timestamp":1790362956000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12962-026-00781-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["781"],"URL":"https:\/\/doi.org\/10.1186\/s12962-026-00781-6","relation":{},"ISSN":["1478-7547"],"issn-type":[{"value":"1478-7547","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"assertion":[{"value":"13 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Since this study did not involve human participants and the selected sources are publicly available, ethical approval was not required.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"117"}}